Staff editor

The gut microbiome: emerging therapeutic perspectives in multiple sclerosis and type 1 diabetes

Marika Falcone of San Raffaele Hospital in Milan discusses the growing evidence linking the gut microbiome to extra-intestinal autoimmune diseases.

Microbiome innovation meets space exploration: a new frontier for human adaptation

Pierre Burguière, founder of Microbiome Futures, and Christian Roghi, founder of Bridgyz, reflect on a groundbreaking Pharmabiotics 2026 session dedicated to the intersection of microbiome science and space exploration.

Discover dsm-firmenich’s pioneering longevity science at Vitafoods 2026

Visitors to booth #3C88 in Barcelona this May can explore how dsm-firmenich is unlocking increased health expectancy with the latest science-backed innovations targeting the cellular hallmarks of aging.

Gut bacteria may help protect pregnancies by keeping the immune system in balance

The study suggest that gut microbiota regulates key immune cells during pregnancy, and when this system is altered, the risk of pregnancy loss rises.

IBD and the microbiome: between biological complexity and emerging therapeutic signals

Maurizio Vecchi, gastroenterologist at Policlinico of Milan (Italy), discussed the current and potential role of the microbiome in inflammatory bowel disease (IBD).

Oral Microbiome: a new window on systemic health—and a clinical opportunity for evidence-based probiotics

Gianfranco Grompone, Chief Scientific Officer at BioGaia GA, discusses the new evidences about oral microbiome.

Pregnancy: how dysbiosis may affect placentation, maternal immunity, and the risk of neonatal sepsis

Maria Rescigno (Humanitas University, Rozzano, Milan) discusses the role of dysbiosis during pregnancy and the perinatal period, outlining two potential clinical trajectories.

Postbiotics: the story, the evidences, the ingredient

How postbiotics are reshaping dietary supplements and pharma: key insights from Humiome® Post LB.

Gut microbiota, intestinal barrier, and sepsis: from dysbiosis to probiotics—what preclinical evidence suggests

Francesco Franceschi from Policlinico Universitario A. Gemelli IRCCS (Roma) focuses on bacterial translocation across a compromised intestinal barrier as a plausible pathway contributing to sepsis.

Microbiome testing for post-infectious IBS: a pilot “microbe-informed” approach presented in Brussels

William Fusco, gastroenterologist at Policlinico Universitario Agostino Gemelli, highlighted a recently published pilot study on post-infectious irritable bowel syndrome (IBS) framed within microbial precision medicine and biomarker-driven care.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.